Background: Apolipoprotein ε4 allele () is the strongest genetic risk factor for Alzheimer's disease and seems to be related to cognitive decline and damaged event-related potential P300, which is a sensitive measure to assess cognitive processing.
Objective: This research aims to critically review the existing scientific evidence regarding the association between and P300.
Methods: A systematic review was carried out up to January 2020 on the following databases: Web of Science, Scopus and Medline/PubMed. Articles were considered for inclusion if they are original research that provided information regarding the association between and P300, available in English, Spanish, or Portuguese, and available in full text. The methodological quality of the studies selected was evaluated using the quality assessment tool for observational cohort and cross-sectional studies recommended by Cochrane.
Results: Out of 993 studies, 14 met the inclusion criteria. The results obtained showed that is related to a longer P300 latency. However, the data supplied do not allow us to confirm if this relationship also occurs in amplitude measures. Moreover, it was observed that genotype may influence P300 in different ages, from younger individuals to demented older people.
Conclusion: Evidence shows that negatively influences cortical activities related to cognitive functions, as indicated by P300.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/1550059420959966 | DOI Listing |
JMIR Res Protoc
January 2025
Department of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Background: To successfully design, develop, implement, and deliver digital health services that provide value, they should be cocreated with patients. However, occasionally, the value may also be codestructed. In the field of health care, the concepts of value cocreation and codestruction still need to be better established within emerging digital health services.
View Article and Find Full Text PDFNeurology
February 2025
Department of Neurology, Yale University School of Medicine, New Haven, CT.
Background And Objectives: The most effective antiseizure medications (ASMs) for poststroke seizures (PSSs) remain unclear. We aimed to determine outcomes associated with ASMs in people with PSS.
Methods: We systematically searched electronic databases for studies on patients with PSS on ASMs.
J Clin Oncol
January 2025
The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia.
Purpose: Over the past 15 years, the landscape of early phase clinical trials (EPCTs) has undergone a remarkable expansion in both quantity and intricacy. The proliferation of sites, trials, sponsors, and contract research organizations has surged exponentially, marking a significant shift in research conduct. However, EPCT operations suffer from numerous inefficiencies, such as cumbersome start-up processes, which are particularly critical when drug safety and the recommended phase II dose need to be established in a timely manner.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milano, Italy.
Background: Randomised trials conducted from 2006 to 2021 indicated that vitamin D supplementation (VDS) was able to prevent severe COVID-19 and acute respiratory infections (ARI). However, larger randomised trials published in 2022 did not confirm the health benefits of VDS in COVID-19 patients.
Objective: To examine through a systematic review with meta-analysis the characteristics of randomised trials on VDS to COVID-19 patients and admission to intensive care unit (ICU), and of randomised trials on VDS for the prevention of ARI.
PLoS One
January 2025
Orthopedics Department, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Objective: The objective of this systematic review and meta-analysis is to clarify the rehabilitation efficacy of virtual reality (VR) balance training after anterior cruciate ligament reconstruction (ACLR).
Methods: This meta-analysis was registered in PROSPERO with the registration number CRD42024520383. The electronic databases PubMed, Web of Science, Cochrane Library, MEDLINE, Embase, China National Knowledge Infrastructure, Chinese Biomedical Literature, China Science and Technology Journal Database, and Wanfang Digital Periodical database were systematically searched to identify eligible studies from their inception up to January 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!